• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/11/21 5:09:01 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care
    Get the next $CLPT alert in real time by email
    SC 13G/A 1 d130847dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2

    (Amendment No. 4)*

     

     

    ClearPoint Neuro, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    55347P209

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    * 

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 55347P209   13G    Page 1 of 5

     

      1.    

      NAMES OF REPORTING PERSONS

     

      Thomas A. Satterfield, Jr.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING PERSON

    WITH

         5.      

      SOLE VOTING POWER

     

      65,000(1)

       6.      

      SHARED VOTING POWER

     

      655,000(2)

       7.      

      SOLE DISPOSITIVE POWER

     

      65,000(1)

       8.      

      SHARED DISPOSITIVE POWER

     

      655,000(2)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      720,000

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      4.0%(3)

    12.  

      TYPE OF REPORTING PERSON

     

      IN

     

    (1)

    Includes 50,000 shares with respect to which the reporting person may acquire beneficial ownership within 60 days pursuant to the exercise of warrants to purchase shares of common stock of the issuer.

    (2)

    Includes 350,000 shares with respect to which the reporting person may acquire beneficial ownership within 60 days pursuant to the exercise of warrants to purchase shares of common stock of the issuer.

    (3)

    Based on 16,869,528 shares of common stock of the issuer outstanding as of November 10, 2020, as reported by the issuer in its Quarterly Report on Form 10-Q for the period ended September 30, 2020, filed with the Securities and Exchange Commission on November 12, 2020, and a total of 400,000 shares with respect to which the reporting person may acquire beneficial ownership within 60 days pursuant to the exercise of warrants to purchase shares of common stock of the issuer.


    CUSIP No. 55347P209   13G    Page 2 of 5

     

    SCHEDULE 13G

     

    Item 1.

     

      (a)

    Name of Issuer:

    MRI Interventions, Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    5 Musick

    Irvine, California 92618

     

    Item 2.

     

      (a)

    Name of Person Filing:

    Thomas A. Satterfield, Jr.

     

      (b)

    Address of Principal Business Office or, if none, Residence:

    Thomas A. Satterfield, Jr.

    2609 Caldwell Mill Lane

    Birmingham, Alabama 35243

     

      (c)

    Citizenship:

    Incorporated by reference from Item 4 of the Cover Page.

     

      (d)

    Title of Class of Securities:

    Incorporated by reference from the Cover Page.

     

      (e)

    CUSIP Number:

    Incorporated by reference from the Cover Page.

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or §§ 240.13d-2(b) or (c), check whether the person filing is a:

    Not Applicable.

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    Incorporated by reference from Item 9 of the Cover Page.

     

      (b)

    Percent of class:

    Incorporated by reference from Item 11 of the Cover Page.


    CUSIP No. 55347P209   13G    Page 3 of 5

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote

    Incorporated by reference from Item 5 of the Cover Page.

     

      (ii)

    Shared power to vote or to direct the vote

    Incorporated by reference from Item 6 of the Cover Page.

     

      (iii)

    Sole power to dispose or to direct the disposition of

    Incorporated by reference from Item 7 of the Cover Page.

     

      (iv)

    Shared power to dispose or to direct the disposition of

    Incorporated by reference from Item 8 of the Cover Page.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    With respect to the beneficial ownership reported for Thomas A. Satterfield, Jr., 30,000 shares and 100,000 warrants are held by Tomsat Investment & Trading Co., Inc., a corporation wholly owned by Mr. Satterfield and of which he serves as President; and 210,000 shares are held by Caldwell Mill Opportunity Fund, which fund is managed by an entity of which Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager.

    Additionally, Mr. Satterfield has a limited power of attorney for voting and disposition purposes with respect to (i) 65,000 shares and (ii) 250,000 shares that may be acquired within 60 days pursuant to the exercise of warrants to purchase shares of common stock of the issuer warrants held by A.G. Family L.P., which has the right to receive or the power to direct the receipt of the proceeds from the sale of its shares.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not Applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not Applicable.


    CUSIP No. 55347P209   13G    Page 4 of 5

     

    Item 10.

    Certifications.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    CUSIP No. 55347P209   13G    Page 5 of 5

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 11, 2021

      Date

    /s/ Thomas A. Satterfield, Jr.

    Thomas A. Satterfield, Jr.
    Get the next $CLPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLPT

    DatePrice TargetRatingAnalyst
    7/25/2024$10.00Buy
    B. Riley Securities
    10/24/2023$8.00Buy
    Stifel
    2/16/2023$14.00Buy
    B. Riley Securities
    4/5/2022$15.00Buy
    B. Riley Securities
    More analyst ratings

    $CLPT
    SEC Filings

    View All

    Amendment: ClearPoint Neuro Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - ClearPoint Neuro, Inc. (0001285550) (Filer)

    2/5/26 4:25:56 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    SEC Form D filed by ClearPoint Neuro Inc.

    D - ClearPoint Neuro, Inc. (0001285550) (Filer)

    2/5/26 8:07:29 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by ClearPoint Neuro Inc.

    EFFECT - ClearPoint Neuro, Inc. (0001285550) (Filer)

    1/23/26 12:15:30 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Burnett Joseph sold $45,823 worth of shares (2,943 units at $15.57) (SEC Form 4)

    4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

    1/27/26 4:27:46 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    CEO and President Burnett Joseph sold $322,400 worth of shares (20,000 units at $16.12) and exercised 20,000 shares at a strike of $2.50 (SEC Form 4)

    4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

    1/13/26 5:00:03 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    Chief Business Officer Stigall L. Jeremy was granted 1 shares, increasing direct ownership by 0.00% to 72,356 units (SEC Form 4)

    4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

    1/5/26 6:57:18 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CLPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain

    Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United StatesSOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the SmartFlow Neuro Cannula using the De Novo pathway. The SmartFlow Neuro Cannula is intended for intraputaminal administration of PTC Therapeutics' gene therapy KEBILIDI™ (eladocagene exuparvovec-tneq) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. This signifies th

    11/13/24 1:20:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro Reports Third Quarter 2024 Results

    Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2024.Third Quarter HighlightsReported quarterly revenue of $8.1 million, a 41% year-over-year increase;Accelerated growth of SmartFrame OR™ platform and ClearPoint Prism® Laser Therapy System, contributing to record navigation and device revenue of $2.9 million, a 53% year-over-year increase;Overall product revenue, inc

    11/7/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024

    President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast TodaySOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced participation in multiple investor conferences and interview formats including Bloomberg Intelligence Vanguards of Healthcare Podcast series published today. The link to the interview published this morning on Bloomberg can be found HERE.Healthcare Conferences with Participation of ClearPoint Neuro Management Include:UBS Global Healthcare Conference in

    10/31/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

    B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $10.00

    7/25/24 8:27:37 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    Stifel initiated coverage on ClearPoint Neuro with a new price target

    Stifel initiated coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $8.00

    10/24/23 6:18:03 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

    B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $14.00

    2/16/23 7:44:43 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

    SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

    11/12/24 2:35:26 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

    SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

    11/8/24 4:33:36 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

    SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

    11/4/24 11:28:38 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    Financials

    Live finance-specific insights

    View All

    ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024

    SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 third quarter on Thursday, November 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 third quarter on Thursday, November 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or a

    10/17/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024

    SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 second quarter on Wednesday, August 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 second quarter on Wednesday, August 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or

    7/17/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024

    SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 first quarter on Tuesday, May 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 first quarter on Tuesday, May 7th, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201

    4/23/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    Leadership Updates

    Live Leadership Updates

    View All

    ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer

    SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mazin Sabra will join the Company effective October 10th as Chief Operating Officer. Mr. Sabra will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to have Mazin join our team and bring his valuable and relevant skill set into our organization," commented Joe Burnett, President and CEO at ClearPoint Neuro. "Our pharma and device partners in many ways view ClearP

    9/20/22 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro, Inc. Announces Appointment of Mary McNamara-Cullinane as Vice President of Regulatory Affairs

    SOLANA BEACH, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mary McNamara-Cullinane has joined the Company as Vice President of Regulatory Affairs. Ms. McNamara-Cullinane will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to welcome Mary to our team as we fully expect her leadership and experience in Regulatory Affairs will contribute immediately to our partners and to patients globally," commented Joe Burnett, Presiden

    8/8/22 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro, Inc. Announces Appointment of Lynnette C. Fallon to Board of Directors

    SOLANA BEACH, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Lynnette C. Fallon has been appointed to the Company's Board of Directors effective immediately. Ms. Fallon will also become a member of the Company's Audit Committee. Ms. Fallon is the Executive Vice President, HR/Legal, General Counsel and Secretary of Axcelis Technologies, Inc. (NASDAQ:ACLS), a provider of equipment and service solutions for the semiconductor manufacturing industry, with locations in eight countries. Ms. Fallon has held her current position sin

    7/15/21 4:30:00 PM ET
    $CLPT
    $ACLS
    Medical/Dental Instruments
    Health Care
    Industrial Machinery/Components
    Technology